Exploratory review of placebo characteristics reported in randomised placebo controlled antidepressant drug trials

Pharmacopsychiatry

Volumn 45, Issue 1, 2012, Pages 20-27

  Hughes, J ^a   Gabbay, M ^b   Funnell, E ^b   Dowrick, C ^b  

^a UCL Hospitals NHS Trust   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

antidepressants; depression; placebo; review

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

AGE; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; EMPATHY; ENVIRONMENT; ETHNICITY; HEALTH BELIEF; HEALTH CARE SYSTEM; HEALTH STATUS; HUMAN; OCCUPATION; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW;

ANTIDEPRESSIVE AGENTS; BIOMEDICAL RESEARCH; DEPRESSION; FEMALE; HUMANS; MALE; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84855351347     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1286260     Document Type: Review

References (127)

1. Murray CJ L, Lopez A D. Alternative projections of mortality and disability by cause 19902020: Global Burden of Disease Study. Lancet: 1997; 349 1498 1504 (Pubitemid 27216360)
2. stn T B, Ayuso-Mateos J L, Chatterji S et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry: 2004; 184 386 392 (Pubitemid 38624764)
3. Anderson I M, Nutt D J, Deakin JF W. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol: 2000; 14 3 20 (Pubitemid 30156533)
4. Chen Y, Kelton C M, Jing Y et al. Utilization, price, and spending trends for antidepressants in the US Medicaid Program. Res Social Adm Pharm: 2008; 4 244 257
5. Mason J, Freemantle N, Young P. The effect of the distribution of Effective Health Care Bulletins on prescribing selective serotonin reuptake inhibitors in primary care. Health Trends: 1999; 30 120 122
6. Moore M, Yuen H M, Dunn N et al. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ: 2009; 339 b3999
7. Whittington C J, Kendall T, Fonagy P et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet: 2004; 363 1341 1345 (Pubitemid 38529872)
8. Turner E H, Matthews A M, Linardatos E et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med: 2008; 358 252 260
9. Walsh B T, Seidman S N, Sysko R et al. Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing. JAMA: 2002; 287 1840 1847 (Pubitemid 34303629)
10. Kirsch I, Moore T J, Scoboria A et al. The Emperors New Drugs: An Analysis of Antidepressant Medication Data Submitted to the U.S. Food and Drug Administration. Prevention & Treatment: 2002; 5 23
11. Khan A, Khan S, Brown W A. Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol: 2002; 5 193 197
12. Reilly D. Randomised controlled trials for homoeopathy. When is useful improvement a waste of time? Double positive paradox of negative trials. BMJ: 2002; 325 41
13. Melander H, Salmonson T, Abadie E et al. A regulatory apologia: a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol: 2008; 18 623 627
14. Kirsch I, Deacon B J, Huedo-Medina T B et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine: 2008; 5 e45
15. Stolk P, ten Berg M J, Hemels ME H et al. Meta-Analysis of Placebo Rates in Major Depressive Disorder Trials. Ann Pharmacother: 2003; 37 1891 1899 (Pubitemid 37466590)
16. Dowrick C F. Beyond Depression: a new approach to understanding and management. Oxford University Press: 2004
17. Rickels R. Use of placebo in clinical trials. Psychopharmacol Bull: 1986; 22 19 24
18. Di Blasi Z, Harkness E, Ernst E et al. Influence of context effects on health outcomes: a systematic review. Lancet: 2001; 357 757 762 (Pubitemid 32217684)
19. Benedetti F, Mayberg H S, Wager T D et al. Neurobiological mechanisms of the placebo effect. J Neurosci: 2005; 25 10390 10402 (Pubitemid 41628443)
20. Colloca L, Benedetti F. Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci: 2005; 6 545 551
21. Stoessl A J, de la Fuente-Fernandez R. Willing oneself better on placebo: effective in its own right. Lancet: 2004; 364 227 228 (Pubitemid 38942802)
22. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev: 2004; 1 CD003012
23. Reilly D. Enhancing human healing: directly studying human healing could help to create a unifying focus in medicine. BMJ: 2001; 322 120 121 (Pubitemid 32116185)
24. De Craen A J, Roos P J, Leonard de Vries A et al. Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. BMJ: 1996; 313 1624 1626 (Pubitemid 27010670)
25. Branthwaite A, Cooper P. Analgesic effects of branding in treatment of headaches. BMJ: 1981; 282 1576 1578 (Pubitemid 11098211)
26. De Craen AJ M, Moerman D E, Heisterkamp S H et al. Placebo effect in the treatment of duodenal ulcer. Br J Clin Pharmacol: 1999; 48 853 860
27. Kaptchuk T J, Goldman P, Stone D A et al. Do medical devices have enhanced placebo effects? J Clin Epidemiol: 2000; 53 786 792 (Pubitemid 30609642)
28. Ulrich R S. View through a window may influence recovery from surgery. Science: 1984; 224 420 421 (Pubitemid 14134006)
29. Smith E B. Effect of investigator bias on clinical trials. Arch Dermatol: 1989; 125 216 218 (Pubitemid 19070206)
30. Moerman D E. Meaning, Medicine and the Placebo Effect. Cambridge University Press: 2002
31. Klosterhalfen S, Enck P. Neurophysiology and psychobiology of the placebo response. Curr Opin Psychiatry: 2008; 21 189 195 (Pubitemid 351339876)
32. Khan A, Brodhead A E, Schwartz K A et al. Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol: 2005; 25 318 324 (Pubitemid 41060250)
33. Moussavi S, Chatterji S, Verdes E et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet: 2007; 370 851 858 (Pubitemid 47362344)
34. Crow R, Gage H, Hampson S et al. The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review. Health Technol Assess: 1999; 3 3
35. Sullivan M D, Katon W J, Russo J E et al. Patient Beliefs Predict Response to Paroxetine Among Primary Care Patients with Dysthymia and Minor Depression. J Am Board Fam Pract: 2003; 16 22 31
36. Ciechanowski P, Katon W J. The interpersonal experience of health care through the eyes of patients with diabetes. Soc Sci Med: 2006; 63 3067 3079 (Pubitemid 44755013)
37. Horwitz R I, Viscoli C M, Donaldson R M et al. Treatment adherence and risk of death after a myocardial infarction. Lancet: 1990; 336 542 545 (Pubitemid 20278106)
38. Krupnick J L, Sotsky S M, Simmens S et al. The Role of the therapeutic alliance in psychotherapy pharmacotherapy outcome: findings in the national institute of mental health treatment of depression collaborative research program. J Consult Clin Psychol: 1996; 64 532 539 (Pubitemid 26230547)
39. Moseley J B, OMalley K, Petersen N J et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. NEJM: 2002; 347 81 88 (Pubitemid 34753477)
40. Amsterdam J D, Case W G, Csanalosi E et al. A double-blind comparative trial of zimelidine, amitriptyline, and placebo in patients with mixed anxiety and depression. Pharmacopsychiatry: 1986; 19 115 119 (Pubitemid 16074963)
41. Amsterdam J D, Dunner D L, Fabre L F et al. Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression. Pharmacopsychiatry: 1989; 22 137 143 (Pubitemid 19176091)
42. Bakish D, Bradwejn J, Nair N et al. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl): 1992; 106 suppl S98 S101
43. Bremner J D. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry: 1995; 56 519 525
44. Byerley W F, Reimherr F W, Wood D R et al. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol: 1988; 8 112 115
45. Chouinard G, Saxena B M, Nair NP V et al. A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord: 1994; 32 105 114
46. Claghorn J, Gershon S, Goldstein B J et al. A double-blind evaluation of zimelidine in comparison to placebo and amitriptyline in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry: 1983; 7 367 382 (Pubitemid 13077550)
47. Claghorn J L, Kiev A, Rickels K et al. Paroxetine versus placebo: a double-blind comparison in depressed patients. J Clin Psychiatry: 1992; 53 434 438 (Pubitemid 23018086)
48. Claghorn J L, Lesem M D. A double-blind placebocontrolled study of Org 3770 in depressed outpatients. J Affect Disord: 1995; 34 165 171
49. Claghorn J L, Earl C Q, Walczak D D et al. Fluvoxamine maleate in the treatment of depression: a singlecenter, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol: 1996; 16 113 120 (Pubitemid 26142899)
50. Cohn C K, Robinson D S, Roberts D L et al. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry: 1996; 57 02 15 18 (Pubitemid 26143974)
51. Cohn J B, Collins G, Ashbrook E et al. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol: 1989; 4 313 322
52. Cohn J B, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry: 1985; 46 26 31 (Pubitemid 15139186)
53. Conti L, DellOsso L. Clinical predictors of response to fluvoxamine, imipramine, and placebo. New Trends Exp Clin Psychiatry: 1989; 5 221 229
54. Cunningham L A, Borison R L, Carman J S et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol: 1994; 14 99 106 (Pubitemid 24120707)
55. Cunningham L A. for the Venlafaxine XR 208 Study Group Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry: 1997; 9 157 164 (Pubitemid 27470387)
56. Davidson J R, Giller E L, Zisook S et al. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatry: 1988; 45 120 127 (Pubitemid 18052842)
57. Dominguez R A, Goldstein B J, Jacobson A F et al. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. J Clin Psychiatry: 1985; 46 84 87 (Pubitemid 15147502)
58. Dunlop S R, Dornseif B E, Wernicke J F et al. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull: 1990; 26 173 180 (Pubitemid 20291871)
59. Fabre L F, Abuzzahab F S, Amin M et al. Sertraline safety and efficacy in major depression: a doubleblind fixed-dose comparison with placebo. Biol Psychiatry: 1995; 38 592 602
60. Feighner J P, Aden G C, Fabre L F et al. Comparison of alprazolam, imipramine, and placebo in the treatment of depression. JAMA: 1983; 249 3057 3064 (Pubitemid 13098488)
61. Feighner J P, Boyer W F. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand Suppl: 1989; 350 125 129 (Pubitemid 19236657)
62. Ferguson J M, Mendels J, Manowitz N R. for the Prothiaden Collaborative Study Group Dothiepin versus doxepin in major depression: results of a multicenter, placebo-controlled trial. J Clin Psychiatry: 1994; 55 258 263 (Pubitemid 24235840)
63. Fontaine R, Ontiveros A, Elie R et al. A doubleblind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry: 1994; 55 234 241 (Pubitemid 24235835)
64. Gelenberg A J, Wojcik J D, Falk W E et al. Clovoxamine in the treatment of depressed outpatients: a double-blind, parallelgroup comparison against amitriptyline and placebo. Compr Psychiatry: 1990; 31 307 314 (Pubitemid 20333844)
65. Giller E J, Bialos D, Harkness L et al. Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid. J Clin Psychiatry: 1984; 45 44 48 (Pubitemid 14090372)
66. Halikas J A. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol: 1995; 10 S125 S133
67. Heiligenstein J H, Tollefson G D, Faries D E. Response patterns of depressed outpatients with and without melancholia: a double-blind, placebocontrolled trial of fluoxetine versus placebo. J Affect Disord: 1994; 30 163 173 (Pubitemid 24087681)
68. Hormazabal L, Omer L M, Ismail S. Cianopramine and amitriptyline in the treatment of depressed patients: a placebo-controlled study. Psychopharmacology (Berl): 1985; 86 205 208 (Pubitemid 15077755)
69. Itil T M, Shrivastava R K, Mukherjee S et al. A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br J Clin Pharmacol: 1983; 15 03 433S 438S (Pubitemid 13126949)
70. Khan A, Dager S R, Cohen S et al. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology: 1991; 4 125 130
71. Khan M C. A randomised, double-blind, placebocontrolled, 5-weeks study of Org 3770 (mirtazapine) in major depression. HumPsychopharmacol: 1995; 10 S119 S124
72. Laakman G, Faltermaier-Temizel M, Bossert-Zaudig S et al. Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo. Psychopharmacology (Berl): 1995; 120 109 115
73. Lapierre Y D, Silverstone P, Reesal R T et al. A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe major depression. J Clin Psychopharmacol: 1998; 18 268 273 (Pubitemid 28353868)
74. Lineberry C G, Johnston J A, Raymond R N et al. A fixed-dose (300mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry: 1990; 51 194 199 (Pubitemid 20159096)
75. Lipman R S, Covi L, Rickels K et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders, I: efficacy in depressed outpatients. Arch Gen Psychiatry: 1986; 43 68 77 (Pubitemid 16148973)
76. Lydiard R B, Stahl S M, Hertzman M et al. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry: 1997; 58 484 491 (Pubitemid 27527444)
77. Mendels J, Schless A P. Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. J Clin Psychiatry: 1986; 47 357 361 (Pubitemid 16057605)
78. Mendels J, Johnston R, Mattes J et al. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull: 1993; 29 169 174 (Pubitemid 23311520)
79. Merideth C H, Feighner J P. A double-blind, controlled evaluation of zimeldine, imipramine and placebo in patients with primary affective disorders. Acta Psychiatr Scand Suppl: 1983; 308 70 79 (Pubitemid 14186554)
80. Muijen M, Roy D, Silverstone T et al. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand: 1988; 78 384 390
81. Nair N P, Amin M, Holm P et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized, multicentre trial against placebo. J Affect Disord: 1995; 33 1 9
82. Ose E, Holm P. Moclobemide and placebo in mild major depression: a double-blind randomized trial. Psychopharmacology: 1992; 106 S114 S115
83. Peselow E D, Stanley M, Filippi A M et al. The predictive value of the dexamethasone suppression test: a placebo controlled study. Br J Psychiatry: 1989; 155 667 672 (Pubitemid 19269074)
84. Reimherr F W, Wood D R, Byerley B et al. Characteristics of responders to fluoxetine. Psychopharmacol Bull: 1984; 20 70 72 (Pubitemid 14128872)
85. Reimherr F W, Chouinard G, Cohn C K et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry: 1990; 51 (suppl B): 18 27
86. Rickels K, Weise C C, Sandler K et al. Nomifensine, imipramine and placebo in depressed outpatients. Int Pharmacopsychiatry: 1982; 17 73 88 (Pubitemid 12054769)
87. Rickels K, Feighner J P, Smith W T. Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression. Arch Gen Psychiatry: 1985; 42 134 141 (Pubitemid 15246355)
88. Rickels K, Chung H R, Csanalosi I B et al. Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry: 1987; 44 862 866 (Pubitemid 17155443)
89. Rickels K, London J, Fox I et al. Adinazolam, diazepam, imipramine, and placebo in major depressive disorder: a controlled study. Pharmacopsychiatry: 1991; 24 127 131
90. Rickels K, Schweizer E, Clary C et al. Nefazodone and imipramine in major depression: a placebo controlled trial. Br J Psychiatry: 1994; 164 802 805 (Pubitemid 24186900)
91. Rickels K, Derivan A, Kunz N et al. Zalospirone in major depression: a placebocontrolled multicenter study. J Clin Psychopharmacol: 1996; 16 212 217 (Pubitemid 26227918)
92. Robinson D S, Rickels K, Feighner J et al. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol: 1990; 10 03 67S 76S (Pubitemid 20212933)
93. Rudolph R L, Fabre L F, Feighner J P et al. A randomized, placebocontrolled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry: 1998; 59 116 122 (Pubitemid 28150857)
94. Rudolph R L, Feiger A D. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord: 1999; 56 171 181 (Pubitemid 30058219)
95. Rther E, Degner D, Munzel U et al. Antidepressant action of sulpride: results of a placebocontrolled double-blind trial. Pharmacopsychiatry: 1999; 32 127 135 (Pubitemid 29434278)
96. Schatzberg A F. Clinical efficacy of reboxetine in major depression. J Clin Psychiatry: 2000; 61 10 31 38 (two separate trials) (Pubitemid 30485423)
97. Schrader E, Meier B, Brattstroem A. Hypericum treatment of mild-moderate depression in a placebocontrolled study: a prospective, double-blind, randomized, placebo-controlled, multicentre study. Hum Psychopharmacol: 1998; 13 163 169 (Pubitemid 28216247)
98. Schweizer E, Feighner J, Mandos L A et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry: 1994; 55 104 108 (Pubitemid 24116436)
99. Schweizer E, Rickels K, Hassman H et al. Buspirone and imipramine for the treatment of major depression in the elderly. J Clin Psychiatry: 1998; 59 175 183 (Pubitemid 28208332)
100. Silverstone P H, Ravindran A. for the Venlafaxine XR 360 Study Group Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry: 1999; 60 22 28 (Pubitemid 29069881)
101. Smith W T, Glaudin V, Panagides J et al. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull: 1990; 26 191 196 (Pubitemid 20291874)
102. Stahl S M. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry: 2000; 48 894 901
103. Stassen H H, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? survey of results of Zurich meta-analyses. Pharmacopsychiatry: 1996; 29 87 96 (Pubitemid 26150434)
104. Stewart J W, McGrath P J, Liebowitz M R et al. Treatment outcome validation of DSM-III depressive subtypes: clinical usefulness in outpatients with mild to moderate depression. Arch Gen Psychiatry: 1985; 42 1148 1153 (Pubitemid 16191173)
105. Stewart J W, McGrath P J, Quitkin F M et al. Relevance of DSM-III depressive subtype and chronicity of antidepressant efficacy in atypical depression: differential response to phenelzine, imipramine, and placebo. Arch Gen Psychiatry: 1989; 46 1080 1087 (Pubitemid 20016445)
106. Thase M E. for the Venlafaxine XR 209 Study Group Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry: 1997; 58 393 398 (Pubitemid 27438691)
107. Thompson C. Management of depression in real-life settings: knowledge gained from large-scale clinical trials. Int Clin Psychopharmacol: 1994; 9 21 25 (Pubitemid 24210925)
108. Tollefson G D, Holman S L. Analysis of the Hamilton Depression Rating Scale factors from a doubleblind, placebo-controlled trial of fluoxetine in geriatric major depression. Int Clin Psychopharmacol: 1993; 8 253 299
109. UK Moclobemide Study Group A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder. Int Clin Psychopharmacol: 1994; 9 109 113
110. Versiani M, Oggero U, Alterwain P et al. A double blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes. Br J Psychiatry Suppl: 1989; 6 72 77 (Pubitemid 19282142)
111. White K, Razani J, Cadow B et al. Tranylcypromine vs. nortriptyline vs. placebo in depressed outpatients: a controlled trial. Psychopharmacology (Berl): 1984; 82 258 262 (Pubitemid 14184555)
112. Wilcox C S, Cohn J B, Katz B B et al. A double-blind, placebo-controlled study comparing mianserin and amitriptyline in moderately depressed outpatients. Int Clin Psychopharmacol: 1994; 9 271 279 (Pubitemid 24374888)
113. Wilcox C S, Ferguson J M, Dale R N et al. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull: 1996; 32 335 342 (Pubitemid 26365645)
114. NICE Depression: the treatment and management of depression in adults. CG90. National Institute for Health and Clinical Excellence London: 2009
115. Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry: 2008; 16 14 20
116. Clayton A H, Croft H A, Horrigan J P et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry: 2006; 67 736 746 (Pubitemid 43946180)
117. Kasper S, de Swart H, Andersen H F. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry: 2005; 13 884 891 (Pubitemid 46638677)
118. Lepola U M, Loft H, Reines E H. Escitalopram (10-20mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol: 2003; 18 211 217 (Pubitemid 36871872)
119. Nierenburg A A, Grei J H, Mallinckrodt C H et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin: 2007; 23 401 416 (Pubitemid 46333388)
120. Wade A, Lemming O M, Hedegaard K B. Escitalopram 10mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol: 2002; 17 95 102 (Pubitemid 34442189)
121. Henkel V, Seemuller F, Obermeier M et al. Relationship between baseline severity of depression and antidepressant treatment outcome. Pharmacopsychiatry: 2011; 44 27 32
122. Altman D G, Schulz K F, Moher D et al. for the CONSORT Group The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med: 2001; 134 663 694 (Pubitemid 32322245)
123. Antes G. The new CONSORT statement. BMJ: 2010; 340 c1432
124. Finniss D G, Kaptchuk T J, Miller F et al. Biological, clinical, and ethical advances of placebo effects. Lancet: 2010; 375 686 695
125. Rief W, Nestoriuc Y, Weiss S et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord: 2009; 118 1 8
126. Moher D, Schulz K F, Altman D. CONSORT Group (Consolidated Standards of Reporting Trials) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA: 2001; 285 1987 1991 (Pubitemid 32366951)
127. Horder J, Matthews P, Waldmann R. Placebo, Prozac and PLoS: significant lessons for psychopharmacology. J Psychopharmacol: 2010; Jun 22 [Epub ahead of print]